Basaglar Saved Medicaid Millions, Highlighting Benefits Of Competition, JAMA Analysis Shows
Executive Summary
Researchers analyzed usage rates, market share and reimbursement information for the long-acting insulins Lantus and Basaglar to determine the impact from the launch of Lilly’s long-acting Basaglar.
You may also be interested in...
Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.
Lilly/BI's Basaglar: A Rosier Outlook For US Biosimilars?
Sales of the insulin glargine product in its first full year on the market were strong at $432.1m, but Lilly said it is offering steep rebates in exchange for market access and it's not clear that the growth is sustainable if more copies enter the market.